Table 3.

Registered clinical trials of virus-specific T cells in solid organ transplantation

IDCell TherapyTargetsIndication N Solid organ transplantVirus-specific T Lymphocyte DonorPrimary EndpointSite
NCT02779439CTLCMV, EBV, ADVResistance to Rx >2 wk25AnyAllogeneicInfusion related safety at 1 wkSydney
NCT02532452CTLEBV, CMV, ADV, or BKVAny Infection100AnyAllogeneicInfusion related toxicityCincinnati
NCT03010332CTLCMVIntolerant to or failed RxN/AAnyAllogeneic (ATA230)N/AAtara Biotherapeutics
NCT03950414CTLCMVIntolerant to or failed Rx20KidneyAllogenicSafety and tolerabilityMadison, Wisconsin
  • CTL, cytotoxic T lymphocytes; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ADV, adenovirus.